Literature DB >> 21445544

Atypical presentation of Behçet's disease with central nervous system involvement successfully treated with infliximab.

U Studer1, B Ruehe, G Waldegg, I Vajtai, R Escher, D Aeberli.   

Abstract

Central nervous system involvement is a rare and serious complication of Behçet's disease (BD). Herein, we describe a patient with an atypical central lesion, who experienced progressive hypesthesia of the right arm and sensory loss of the trigeminal nerve together with intense headache. A repeated biopsy was necessary to conclusively establish the diagnosis of BD. Therapy with infusions of infliximab led to a remarkable full remission. TNFα-blocking therapy was successfully replaced by azathioprine. The present well-illustrated case demonstrates the difficulty of establishing the diagnosis of BD with central nervous system involvement, the dramatic benefit of short given TNF-α-blocking agent, and the long-term remission with azathioprin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21445544     DOI: 10.1007/s00296-011-1915-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

Review 1.  Behçet's disease.

Authors:  Sara E Marshall
Journal:  Best Pract Res Clin Rheumatol       Date:  2004-06       Impact factor: 4.098

Review 2.  Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature.

Authors:  Nicolò Pipitone; Ignazio Olivieri; Angela Padula; Salvatore D'angelo; Angelo Nigro; Giulio Zuccoli; Luigi Boiardi; Carlo Salvarani
Journal:  Arthritis Rheum       Date:  2008-02-15

3.  Neuro-Behcet's disease mimicking multiple brain tumors: diffusion-weighted MR study and literature review.

Authors:  Jae-Hyeok Heo; Soon-Tae Lee; Kon Chu; Manho Kim
Journal:  J Neurol Sci       Date:  2007-09-12       Impact factor: 3.181

Review 4.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

5.  Neurologic involvement in Behçet's syndrome. A prospective study.

Authors:  P Serdaroğlu; H Yazici; C Ozdemir; S Yurdakul; S Bahar; E Aktin
Journal:  Arch Neurol       Date:  1989-03

6.  Neurological manifestations of Behçet's disease in a Caribbean population: clinical and imaging findings.

Authors:  Annie Lannuzel; Isabelle Lamaury; Dominique Charpentier; Dominique Caparros-Lefebvre
Journal:  J Neurol       Date:  2002-04       Impact factor: 4.849

7.  Azathioprine in Behcet's syndrome: effects on long-term prognosis.

Authors:  V Hamuryudan; Y Ozyazgan; N Hizli; C Mat; S Yurdakul; Y Tüzün; M Senocak; H Yazici
Journal:  Arthritis Rheum       Date:  1997-04

8.  Neuro-Behcet's disease: a masquerader of multiple sclerosis. A prospective study of neurologic manifestations of Behcet's disease in 96 Iranian patients.

Authors:  N Ashjazadeh; A Borhani Haghighi; Sh Samangooie; H Moosavi
Journal:  Exp Mol Pathol       Date:  2003-02       Impact factor: 3.362

Review 9.  The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis.

Authors:  Aksel Siva; Sabahattin Saip
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 10.  Neuro-Behçet's disease: epidemiology, clinical characteristics, and management.

Authors:  Adnan Al-Araji; Desmond P Kidd
Journal:  Lancet Neurol       Date:  2009-02       Impact factor: 44.182

  10 in total
  2 in total

Review 1.  Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.

Authors:  Marko Barešić; Mirna Reihl; Mario Habek; Nenad Vukojević; Branimir Anić
Journal:  Rheumatol Int       Date:  2018-05-17       Impact factor: 2.631

Review 2.  A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.

Authors:  Shojiro Watanabe; Tomomi Aizawa-Yashiro; Kazushi Tsuruga; Manabu Kinjo; Etsuro Ito; Hiroshi Tanaka
Journal:  Rheumatol Int       Date:  2012-12-25       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.